Stockscreener 앱 받기
48.22
0.21%
0.10
시간 외 거래:
48.22
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
California State Teachers Retirement System Grows Stock Holdings in Urogen Pharma $URGN - MarketBeat
Is UroGen Pharma (URGN) Overvalued As Sales Growth And Patent Clarity Lift Confidence? - simplywall.st
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice - Yahoo Finance
UroGen Pharma Ltd (URGN) Competitors 2026 - GuruFocus
(URGN) Volatility Zones as Tactical Triggers - Stock Traders Daily
UroGen Pharma (URGN): TD Bank group discloses 3.37M shares, 6.9% beneficial stake - Stock Titan
UroGen (URGN) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Urogen Pharma (NASDAQ:URGN) Hits New 1-Year HighTime to Buy? - MarketBeat
UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed? - Sahm
Urogen Pharma Ltd at TD Cowen Healthcare Conference Transcript - GuruFocus
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
UroGen Pharma Ltd. (URGN) Options Chain - Yahoo! Finance Canada
Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright - MarketBeat
UroGen Pharma (URGN) Stock Looks Fairly Priced Despite Its 210% Run - Sahm
UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus - Yahoo Finance
Why UroGen Pharma (URGN) Is Up 22.8% After Q2 2026 Revenue Nearly Tripled And Losses Narrowed - Yahoo Finance
UroGen Pharma Ltd. Revenue Breakdown – MUN:UR8 - TradingView
UroGen Pharma Ltd (NASDAQ: URGN) Share Price, URGN Stock News, URGN Share Price & Updates - Kalkine
Bullish: Analysts Just Made An Incredible Upgrade To Their UroGen Pharma Ltd. (NASDAQ:URGN) Forecasts - simplywall.st
URGN Stock Price, Quote & Chart - ChartMill
Oppenheimer Adjusts PT on UroGen Pharma to $60 From $50, Maintains Outperform Rating - Moomoo
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60 - 富途牛牛
Guggenheim raises UroGen Pharma stock price target to $58 on sales beat - Investing.com South Africa
A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $48 to $75 - 富途牛牛
URGN Maintained by Guggenheim -- Price Target Raised to $58.00 - GuruFocus
Urogen Pharma (NASDAQ:URGN) Given New $75.00 Price Target at HC Wainwright - MarketBeat
URGN Maintains Buy by HC Wainwright & Co. -- Price Target Raised to $75 - GuruFocus
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60 - Moomoo
URGN SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
URGN Maintained by TD Cowen -- Price Target Raised to $60 - GuruFocus
UroGen Pharma Ltd (URGN) (Q2 2026) Earnings Call Highlights: Cys - GuruFocus
Urogen Pharma Q2 Earnings Call Highlights - Yahoo Finance
Urogen Pharma (NASDAQ:URGN) Stock Price Up 9.1%Here's Why - MarketBeat
UroGen Pharma Posts 199% Revenue Jump in Q2 2026, Misses on EPS - AlphaStreet
UroGen Pharma 2Q Loss $14.4M >URGN - moomoo.com
Urogen Pharma stock hits 52-week high at 43.97 USD - Investing.com
Earnings call transcript: UroGen Pharma tops Q2 2026 revenue forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: UroGen Pharma tops Q2 2026 revenue forecast - Investing.com
Urogen Pharma stock hits 52-week high at 43.97 USD By Investing.com - Investing.com South Africa
UroGen Pharma Q2 Net Loss Narrows, Revenue Rises - Moomoo
Is UroGen Pharma Ltd (URGN) Overvalued Despite Q2 Revenue of $72 - GuruFocus
Q2 2026 Urogen Pharma Ltd Earnings Call Transcript - GuruFocus
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
UroGen Pharma 2Q Loss/Shr 28c >URGN - Moomoo
Urogen Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (URGN) UroGen Pharma Posts Q2 Net Loss $0.28 a Share, vs. FactSet Est of $0.27 Loss - marketscreener.com
UroGen Q2 revenue jumps to $72.5 million on ZUSDURI launch - Quiver Quantitative
UroGen Reports $72.5M Q2 Revenue, $50.4M ZUSDURI Sales and $14.4M Net Loss - TradingView
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights - marketscreener.com
Press Release: UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights - Moomoo
Q2 2025 Urogen Pharma Ltd Earnings Call Transcript - GuruFocus
Q3 2025 Urogen Pharma Ltd Earnings Call Transcript - GuruFocus
Urogen Pharma Q2 2026 Earnings Call Transcript - MarketBeat
UroGen Pharma faces earnings test as Zusduri growth accelerates - Investing.com
UroGen Pharma faces earnings test as Zusduri growth accelerates By Investing.com - Investing.com Nigeria
Price-Driven Insight from (URGN) for Rule-Based Strategy - news.stocktradersdaily.com
Urogen Pharma (URGN) to Announce Quarterly Earnings on Thursday - MarketBeat
UroGen Pharma schedules Aug. 5 webcast before market open - Stock Titan
Return on invested capital % of UroGen Pharma Ltd. – HAM:UR8 - TradingView
EBITDA of UroGen Pharma Ltd. – HAM:UR8 - TradingView
0.52%
0.07%
자본화:
|
볼륨(24시간):